The U.S. Food and Drug Administration approved Infilbray (venglustat) tablets on November 22, 2026, as the first treatment specifically for the neurological symptoms of Type 3 Gaucher disease in adults and pediatric patients weighing at least 15 kilograms. The drug is a glucosylceramide synthase inhibitor designed to cross the blood-brain barrier, targeting the buildup of harmful substances in the brain that drive the disease’s neurological complications.
The Human Side of a Rare Diagnosis
For families living with Type 3 Gaucher disease, the diagnosis has long carried a difficult split reality. Enzyme replacement therapies like Cerezyme (imiglucerase) can control the systemic manifestations — the enlarged spleens, liver issues, and blood counts — allowing patients near-normal longevity. But those intravenous infusions do not cross the blood-brain barrier. They cannot touch the progressive loss of muscle control, the coordination problems, the speech difficulties, or the cognitive decline that define the neuronopathic form of the disease.
An estimated 1,000 to 1,500 people in the United States have Type 3 Gaucher disease. Globally, it is the most common form, though Type 1 remains more prevalent in the U.S. and Europe. Type 2, an ultra-rare infantile form, is generally fatal by age two. Type 3 sits in a chronic, neuronopathic middle ground: patients survive into adulthood, but the neurological symptoms worsen steadily, affecting daily life and independence.
“For patients with Type 3 Gaucher disease, harmful substances build up in the brain without a way to stop them, but this drug’s ability to cross the blood-brain barrier means it can get to the source of the buildup driving the neurological symptoms,” said Acting FDA Commissioner Kyle Diamantas.
How the Drug Works
Gaucher disease stems from a recessive mutation in the GBA gene on chromosome 1. The mutation leaves the body deficient in glucocerebrosidase, an enzyme that breaks down glucocerebroside (also called glucosylceramide). Without it, this fatty substance accumulates in cells and organs — including the brain in Type 3.

Venglustat takes a different approach than enzyme replacement. It is a substrate reduction therapy: a glucosylceramide synthase inhibitor that dials down the production of the problematic lipid in the first place. Crucially, its molecular design allows it to penetrate the central nervous system, reaching the brain tissue where the neurological damage originates.
What the Trial Showed
The approval rests on the phase 3 LEAP2MONO trial, a double-blind, double-dummy study that randomized 43 patients aged 12 and older who had been stabilized on enzyme replacement therapy for at least three years. Half continued on intravenous imiglucerase every two weeks plus a placebo tablet; half switched to once-daily oral venglustat plus a placebo infusion.
The primary endpoint was a composite neurological measure at 52 weeks, combining the modified Scale for the Assessment and Rating of Ataxia (SARA) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) total scale index score. Ataxia, as defined in the FDA announcement, is the loss of muscle control and coordination.
Patients on venglustat showed statistically significant superiority over those on imiglucerase on this combined measure (P = .0137). The drug also performed as well as enzyme replacement therapy on non-neurological endpoints, including spleen and liver volume and hemoglobin levels. Neither the company nor the FDA has released numerical results for the individual components of the composite score or for secondary endpoints. An open-label extension is ongoing.
Pramod Mistry, director of the Yale Lysosomal Disease Center, called the approval “a major milestone for patients, families, and the global Type 3 Gaucher disease community,” noting that existing therapies have addressed systemic but not neurological disease.
What This Means for Patients
For the first time, a pill taken at home offers a chance to address the ataxia and cognitive impairment that have had no targeted treatment. Aviva Rosenberg, co-founder and chief executive of the Gaucher Community Alliance, described the approval as marking “a long-awaited advancement for those experiencing devastating neurological symptoms of Type 3 Gaucher disease,” adding that patients often face years of diagnostic delays while neurological manifestations progress.
The drug carries significant safety warnings. In the trial, adverse reactions more common with venglustat than imiglucerase included diarrhea (14% vs 0%), splenomegaly (14% vs 0%), nausea (14% vs 5%), depression (10% vs 0%), gastroenteritis (10% vs 0%), and vomiting (10% vs 5%). The label includes warnings for suicidal ideation and behavior, lens opacification (clouding of vision) in pediatric patients, and embryo-fetal toxicity — the latter two risks identified in animal studies. The FDA advises healthcare providers and patients to consult the full prescribing information.
Context and What Comes Next
Sanofi, which manufactures Infilbray, already sells Cerezyme for all Gaucher types and Cerdelga (eliglustat) for Type 1. The company has not yet revealed launch plans or pricing for Infilbray. Analysts estimate peak sales potential at $300 million to $500 million annually, a figure reduced after the drug failed in trials for other indications including autosomal dominant polycystic kidney disease, GM2 gangliosidosis, Parkinson’s disease, and Fabry disease. Infilbray is also under regulatory review for Type 3 Gaucher disease in the European Union and Japan.
Sources
- FDA nod to first treatment for neurological symptoms of Type 3 Gaucher disease
- Gaucher's disease
- FDA Approves Venglustat as First Therapy for Neurological Manifestations of Type 3 Gaucher Disease | NeurologyLive – Clinical Neurology News and Neurology Expert Insights
- Venglustat is approved for neurological symptoms of type 3 Gaucher disease in patients weighing at least 15 kg | 2 Minute Medicine
- FDA clears Sanofi's Type 3 Gaucher therapy Infilbray
Photo: National Cancer Institute / Unsplash (Unsplash License)





